BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takashima Y, Horisawa K, Udono M, Ohkawa Y, Suzuki A. Prolonged inhibition of hepatocellular carcinoma cell proliferation by combinatorial expression of defined transcription factors. Cancer Sci 2018;109:3543-53. [PMID: 30220099 DOI: 10.1111/cas.13798] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen L, Bao Y, Jiang S, Zhong XB. The Roles of Long Noncoding RNAs HNF1α-AS1 and HNF4α-AS1 in Drug Metabolism and Human Diseases. Noncoding RNA 2020;6:E24. [PMID: 32599764 DOI: 10.3390/ncrna6020024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Yang X, Cao N, Chen L, Liu L, Zhang M, Cao Y. Suppression of Cell Tumorigenicity by Non-neural Pro-differentiation Factors via Inhibition of Neural Property in Tumorigenic Cells. Front Cell Dev Biol 2021;9:714383. [PMID: 34595169 DOI: 10.3389/fcell.2021.714383] [Reference Citation Analysis]
3 Takashima Y, Hamano M, Fukai J, Iwadate Y, Kajiwara K, Kobayashi T, Hondoh H, Yamanaka R. GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. Sci Rep 2020;10:8435. [PMID: 32439996 DOI: 10.1038/s41598-020-65463-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 El-Nakeep S. Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises). World J Gastrointest Pathophysiol 2022; 13(1): 1-14 [PMID: 35116176 DOI: 10.4291/wjgp.v13.i1.1] [Reference Citation Analysis]
5 Thanan R, Kaewlert W, Sakonsinsiri C, Chaiprasert T, Armartmuntree N, Muengsaen D, Techasen A, Klanrit P, Lert-Itthiporn W, Pinlaor S, Pairojkul C. Opposing Roles of FoxA1 and FoxA3 in Intrahepatic Cholangiocarcinoma Progression. Int J Mol Sci 2020;21:E1796. [PMID: 32151057 DOI: 10.3390/ijms21051796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
6 Nenu I, Stefanescu H, Procopet B, Sparchez Z, Minciuna I, Mocan T, Leucuta D, Morar C, Grigorescu M, Filip GA, Socaciu C. Navigating through the Lipid Metabolism Maze: Diagnosis and Prognosis Metabolites of Hepatocellular Carcinoma versus Compensated Cirrhosis. JCM 2022;11:1292. [DOI: 10.3390/jcm11051292] [Reference Citation Analysis]
7 Takashima Y, Kawaguchi A, Sato R, Yoshida K, Hayano A, Homma J, Fukai J, Iwadate Y, Kajiwara K, Ishizawa S, Hondoh H, Nakano M, Ogawa S, Tashiro K, Yamanaka R. Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL. Sci Rep 2019;9:10004. [PMID: 31292525 DOI: 10.1038/s41598-019-46473-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
8 Takashima Y, Kawaguchi A, Iwadate Y, Hondoh H, Fukai J, Kajiwara K, Hayano A, Yamanaka R. miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma. PLoS One 2020;15:e0229577. [PMID: 32101576 DOI: 10.1371/journal.pone.0229577] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Takashima Y, Horisawa K, Udono M, Ohkawa Y, Suzuki A. Prolonged inhibition of hepatocellular carcinoma cell proliferation by combinatorial expression of defined transcription factors. Cancer Sci 2018;109:3543-53. [PMID: 30220099 DOI: 10.1111/cas.13798] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
10 Nia A, Dhanasekaran R. Genomic Landscape of HCC. Curr Hepatol Rep 2020;19:448-61. [PMID: 33816052 DOI: 10.1007/s11901-020-00553-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ma H, Zhang Q, Yang X, Hu Y, Zhang J, Chen L, Zhao B, Yang W, Xu R, Duan B. HNF4A Regulates the Proliferation and Tumor Formation of Cervical Cancer Cells through the Wnt/β-Catenin Pathway. Oxidative Medicine and Cellular Longevity 2022;2022:1-17. [DOI: 10.1155/2022/8168988] [Reference Citation Analysis]
12 Ren J, Liu Y, Wang S, Wang Y, Li W, Chen S, Cui D, Yang S, Li MY, Feng B, Lai PBS, Chen GG. The FKH domain in FOXP3 mRNA frequently contains mutations in hepatocellular carcinoma that influence the subcellular localization and functions of FOXP3. J Biol Chem 2020;295:5484-95. [PMID: 32198183 DOI: 10.1074/jbc.RA120.012518] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Lu Y, Xu D, Peng J, Luo Z, Chen C, Chen Y, Chen H, Zheng M, Yin P, Wang Z. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1. EBioMedicine 2019;44:403-18. [PMID: 31103629 DOI: 10.1016/j.ebiom.2019.05.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Zou N, Zhang X, Li S, Li Y, Zhao Y, Yang X, Zhu S. Elevated HNF1A expression promotes radiation-resistance via driving PI3K/AKT signaling pathway in esophageal squamous cell carcinoma cells. J Cancer 2021;12:5013-24. [PMID: 34234870 DOI: 10.7150/jca.58023] [Reference Citation Analysis]
15 Zheng BN, Ding CH, Chen SJ, Zhu K, Shao J, Feng J, Xu WP, Cai LY, Zhu CP, Duan W, Ding J, Zhang X, Luo C, Xie WF. Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α. Theranostics 2019;9:2606-17. [PMID: 31131056 DOI: 10.7150/thno.32344] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
16 Simon J, Ouro A, Ala-Ibanibo L, Presa N, Delgado TC, Martínez-Chantar ML. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover. Int J Mol Sci 2019;21:E40. [PMID: 31861664 DOI: 10.3390/ijms21010040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
17 Inada H, Udono M, Matsuda-Ito K, Horisawa K, Ohkawa Y, Miura S, Goya T, Yamamoto J, Nagasaki M, Ueno K, Saitou D, Suyama M, Maehara Y, Kumamaru W, Ogawa Y, Sekiya S, Suzuki A. Direct reprogramming of human umbilical vein- and peripheral blood-derived endothelial cells into hepatic progenitor cells. Nat Commun 2020;11:5292. [PMID: 33087715 DOI: 10.1038/s41467-020-19041-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Teeli AS, Łuczyńska K, Haque E, Gayas MA, Winiarczyk D, Taniguchi H. Disruption of Tumor Suppressors HNF4α/HNF1α Causes Tumorigenesis in Liver. Cancers (Basel) 2021;13:5357. [PMID: 34771521 DOI: 10.3390/cancers13215357] [Reference Citation Analysis]
19 Alunni-Fabbroni M, Rönsch K, Huber T, Cyran CC, Seidensticker M, Mayerle J, Pech M, Basu B, Verslype C, Benckert J, Malfertheiner P, Ricke J. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J Transl Med 2019;17:328. [PMID: 31570105 DOI: 10.1186/s12967-019-2079-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
20 Zhong Y, Qi H, Li X, An M, Shi Q, Qi J. Tumor supernatant derived from hepatocellular carcinoma cells treated with vincristine sulfate have therapeutic activity. Eur J Pharm Sci 2020;155:105557. [PMID: 32946955 DOI: 10.1016/j.ejps.2020.105557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]